14389-87-8

Upstream product

• 100-39-0 benzyl bromide 
• 69-72-7 salicylic acid 
• 7221-40-1 benzyldimethyl-2-hydroxyethyl-ammonium chloride 
• 100-44-7 benzyl chloride 
• 606-45-1 2-methoxybenzoic acid methyl ester 
• 68-12-2 N,N-dimethyl-formamide 
• 20194-18-7 sodium phenyl-methanolate 
• 103-83-3 N,N'-dimethylbenzylamine 
• 119-36-8 methyl salicylate 

Downstream Products

• 14389-86-7 2-benzyloxybenzoic acid 
• 71367-02-7 C₁₄H₁₁⁽²⁾HO₂ 
• 100-51-6 benzyl alcohol 
• 118-58-1 benzyl salicylate 
• 6702-58-5 4-methoxy-9H-xanthen-9-one 
• 1258196-72-3 (2-(benzyloxy)phenyl)(2,4,5-trimethoxyphenyl)methanone 
• 1258196-68-7 [2-(benzyloxy)phenyl](1,4-dimethoxynaphthalen-2-yl)methanone 
• 1258196-71-2 [2-(benzyloxy)phenyl](2,5-dimethoxyphenyl)methanone 
• 142819-91-8 1-(2-benzyloxyphenyl-2-diazopropan-1-one 
• 195813-61-7 3-(2'-hydroxyphenyl)-5-(2-benzyloxyphenyl)pyrazole 
• 164170-38-1 2'-(2-benzyloxybenzoyloxy)acetophenone 
• 893393-33-4 C₁₇H₁₅⁽²⁾HO 

Relevant academic research and scientific papers

Facile alkoxyl exchange of 2-methoxybenzoates via nucleophilic aromatic substitution with sodium alkoxides in dimethylformamide

Methyl 2-methoxybenzoate undergoes facile nuclear-methoxyl displacement by treatment with sodium butexide or isopropoxide in dimethylformamide.

Synthesis and evaluation of new sesamol-based phenolic acid derivatives with hypolipidemic, antioxidant, and hepatoprotective effects

The objective of this study is to synthesize a series of sesamol-based phenolic acid derivatives, which were designed by combination principle. The hypolipidemic activity of all these compounds was preliminarily screened by acute hyperlipidemic mice model induced by Triton WR 1339, in which compound T6 exhibited more significant reducing plasma TG and TC than fenofibrate. Compound T6 was also found to obviously decrease TG and TC both in the plasma and hepatic tissue of high-fat-diet-induced hyperlipidemic mice. Moreover, T6 showed hepatoprotective effects, which remarkable amelioration in characteristic liver enzymes was examined and the histopathological observation displayed that compound T6 inhibited lipids accumulation in the hepatic. The levels of PPAR-α receptor related to lipids metabolism in hepatic tissue were upregulated after T6 treatment. Other potent effects of T6 such as antioxidant and anti-inflammatory activity were also observed. On the bases of these findings, compound T6 may serve as an effective hypolipidemic and hepatoprotective agent. [Figure not available: see fulltext.]

GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF

There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis.

How Many O-Donor Groups in Enterobactin Does It Take to Bind a Metal Cation?

The E. coli siderophore enterobactin, the strongest FeIII chelator known to date, forms hexacoordinate complexes with SiIV, GeIV, and TiIV. Synthetic protocols have been developed to prepare non-symmetric entero

Highly efficient and green esterification of carboxylic acids in deep eutectic solvents without any other additives

A protocol that carboxylic acids esterifies with the quaternary ammonium salt of deep eutectic solvent (DES) is presented, which opens a new access to ester using DES as alkylating agent, solvent, and catalyst. The reaction runs smoothly in DES without any other additives. Substituted cinnamic acids, aromatic acids, and aliphatic acids can be esterified in moderate to good yields. The advantages of this reaction include excellent functional group compatibility and simple reaction procedure.

COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION

Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis. As solid tumors outgrow the surrounding vasculature, they encounter microenvironments with a limited supply of nutrients leading to a glucose deprived environment in some regions of the tumor. Cancer cells living in the glucose deprived environment undergo changes to prevent glucose deprivation-induced apoptosis. Knowing how cancer cells evade apoptosis induction is also likely to yield valuable information and knowledge of how to overcome the resistance to apoptosis induction in cancer cells. Disclosed herein are novel anticancer compounds that inhibit basal glucose transport, resulting in tumor suppression and new methods for the study of glucose deprivation in animal cancer research.

CAN-mediated oxidations for the synthesis of xanthones and related products

Reaction of (2,4,5-trimethoxyphenyl)(2-hydroxyphenyl)methanone with ceric ammonium nitrate furnished the xanthone, 2,3-dimethoxy-9H-xanthen-9-one. Under the same conditions the related (1,4-dimethoxynaphthalen-2-yl)(2-hydroxyphenyl) methanone resulted in the formation of 12a-methoxy-5H-benzo[c]xanthenes 5,7(12aH)-dione. Other examples of this novel transformation are also outlined.

Novel inhibitors of basal glucose transport as potential anticancer agents

Cancer cells commonly show increased levels of glucose uptake and dependence. A potential strategy for the treatment of cancer may be the inhibition of basal glucose transport. We report here the synthesis of a small library of polyphenolic esters that inhibit basal glucose transport in H1299 lung and other cancer cells. These basal glucose transport inhibitors also inhibit cancer cell growth in H1299 cells, and these two activities appear to be correlated.

Palladium-catalyzed ring enlargement of aryl-substituted methylenecyclopropanes to cyclobutenes

Methylenecyclopropanes 1 could be converted to the corresponding cyclobutenes 2 under the catalysis of palladium acetate in the presence of metal bromide in 1,2-dichloroethane under mild conditions. A plausible reaction mechanism has been proposed on the

Modulators of protein tyrosine phosphatases (PTPases)

The present invention provides novel thienopyridines, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP (TC-PTP), wherein X, R1, R2, R3, and R4 are defined more fully in the description. The compounds are useful in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.